Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Scopolamine HBT IM Safety and PK Study
NCT04314713Phase 1Terminated
- Sponsor
- Battelle
- Start
- Jun 2020
- Primary completion
- Apr 2021
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of scopolamine in organophosphate poisoning (6 arms), sponsored by Battelle. Primary endpoints: Degree and Number of Adverse Events Experienced by Subjects at 30 Days, Cmax of Ascending Doses of Scopolamine HBT at 30 Days and 7 more. Started Jun 2020; status: terminated.
02
Drugs
scopolamine
03
Conditions
organophosphate poisoning
Beyond the preview
Go deeper on NCT04314713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04314713.